Ketamine Therapy for PTSD: Evidence, Cost, and Finding a Provider

Ketamine is not FDA-approved for PTSD. That's the starting point, and it matters.

The only FDA-approved medications for PTSD are sertraline (Zoloft) and paroxetine (Paxil) — both SSRIs — with remission rates of just 20–30%. The 2023 VA/DoD Clinical Practice Guideline explicitly recommends against ketamine for PTSD, citing insufficient evidence. Yet dozens of VA facilities are running ketamine programs. Veterans are traveling to private clinics. And researchers are producing data that the guidelines haven't yet caught up with.

The clinical picture is more nuanced than any single position captures. Here's what the evidence actually shows.

The Evidence: Small Trials Show Promise, the Largest Trial Did Not

Early Controlled Data

The first rigorous RCT examining ketamine for PTSD came from Mount Sinai (Feder et al., JAMA Psychiatry, 2014, n=41). A single IV infusion produced a 12.7-point greater reduction on the Impact of Event Scale-Revised (IES-R) versus midazolam placebo at 24 hours — a meaningful difference within a day of treatment.

A follow-up study from the same group (Feder et al., AJP, 2021, n=30) extended to a full course of six IV infusions over two weeks. The result: an 11.88-point improvement on the CAPS-5 (the gold-standard PTSD severity scale) versus midazolam, with a large effect size (Cohen's d=1.13). Symptom improvements lasted a median of 27.5 days after the final infusion.

These are compelling numbers — large effect sizes, rapid onset, a credible active comparator.

The Largest Trial Found No Benefit

The CAP trial (Abdallah and Krystal, Neuropsychopharmacology, 2022) is the study that stopped the momentum toward clinical adoption. It enrolled 158 veterans across VA and military sites and randomized them to saline placebo, low-dose ketamine (0.2 mg/kg), or standard-dose ketamine (0.5 mg/kg) for eight infusions over four weeks.

The result: no significant advantage of ketamine over placebo on PTSD symptoms, whether measured by PCL-5 or CAPS-5. Ketamine did reduce comorbid depressive symptoms — but not PTSD specifically.

A 2024 meta-analysis by Borgogna et al. (European Journal of Psychotraumatology, 6 RCTs, n=221) reached a similar conclusion: the overall effect size was g=0.27, which after correction for likely publication bias dropped to g=0.20 — statistically non-significant.

Honest Assessment

The early Mount Sinai results and the CAP trial are genuinely in conflict. Sample sizes differ. Patient populations differ. The Mount Sinai studies enrolled civilian patients with PTSD; the CAP trial enrolled veterans. Whether veteran-specific factors, comorbidities, or the specific infusion protocol account for the divergence isn't resolved.

What the data does not support is confident clinical use of ketamine alone for PTSD based on current evidence — which is why the VA/DoD guideline landed where it did.

The Emerging Answer: Ketamine Combined With Psychotherapy

The most consistent thread in recent research is that ketamine may be most useful not as a standalone PTSD treatment but as a tool to enhance trauma-focused psychotherapy.

Feder 2025 (Journal of Clinical Psychiatry, April 2025, n=13): Six IV infusions combined with five sessions of Written Exposure Therapy. 69% of participants met treatment response criteria (≥30% CAPS-5 reduction), with an effect size of d=1.9. The study was uncontrolled — no comparison arm — but the results are striking.

Beaglehole 2025 (BJPsych Open, October 2025, n=33): The first RCT examining intramuscular ketamine in treatment-refractory PTSD, providing early evidence that IM administration may be a viable option for this population.

MacConnel 2025 (Journal of Psychopharmacology, n=117): A retrospective analysis of IV ketamine delivered with psychedelic-therapy elements — 75.2% of patients showed clinically meaningful improvement and 61.5% met remission criteria for PTSD.

The Yale protocol (Harpaz-Rotem): A single ketamine infusion followed by four days of intensive exposure therapy, with the timing of therapy deliberately aligned to the BDNF peak that occurs approximately 24 hours post-infusion. The rationale is that the 24–72 hour post-infusion window represents a period of elevated neuroplasticity — potentially making trauma-focused therapy more effective during this window than at baseline.

Why Ketamine Works Differently Than SSRIs for Trauma

SSRIs slowly modulate serotonin reuptake and typically require 4–8 weeks of consistent dosing to produce effects. Ketamine acts on the glutamate system and produces measurable changes within hours. But the mechanistic distinction goes deeper than speed.

Three trauma-relevant mechanisms that SSRIs don't engage:

1. Fear extinction enhancement. NMDA receptors in the prefrontal cortex are critical for extinction learning — the brain's ability to update fear memories with new safety information. Ketamine accelerates fear extinction via mTORC1 signaling, potentially making exposure therapy more effective when administered in combination.

2. Memory reconsolidation disruption. A 2024 study in Neuron showed that ketamine administered during memory re-exposure reduced the reactivity of traumatic memory engram cells in the amygdala. When a traumatic memory is retrieved, it temporarily becomes unstable and malleable — this reconsolidation window may be a target for ketamine's effects.

3. Default mode network disruption. The default mode network (DMN) is hyperactive in PTSD, driving rumination and intrusive memories. Ketamine rapidly reduces DMN connectivity — an effect that may underlie some of the immediate symptom relief observed in trials.

The BDNF peak at approximately 24 hours post-infusion creates what researchers call a "neuroplasticity window" of 24–72 hours. Several protocols are designed specifically around this window, timing trauma-focused therapy to coincide with peak plasticity.

PTSD Protocols Differ From Depression Protocols

There is no standardized PTSD ketamine protocol. Over 500 clinics in the US are currently using varying approaches, with no consensus on dose, frequency, or adjunctive components.

By contrast, the depression protocol is relatively standardized: six infusions at 0.5 mg/kg over three weeks, no psychotherapy required. For PTSD, the emerging clinical direction emphasizes combination with evidence-based trauma psychotherapy — though the specific modality varies by clinic and researcher.

Therapy modalities being paired with ketamine in current studies and clinical programs:

Prolonged Exposure (Yale protocol, Harpaz-Rotem)
Written Exposure Therapy (Mount Sinai)
EMDR
TIMBER (mindfulness-based extinction protocol)
Cognitive Processing Therapy

If you're pursuing ketamine for PTSD, ask specifically whether the clinic pairs infusions with any trauma-focused therapy and what their experience with PTSD patients looks like. A clinic experienced primarily in treating depression may not have the same protocol sophistication for trauma.

Veterans: The VA Landscape

The VA officially recommends against ketamine for PTSD per its 2023 clinical practice guideline. In practice, the situation is more complicated.

VA programs that exist despite the guideline:

The Central Arkansas VA operates a standalone Mental Health Ketamine clinic. Its published outcomes show 85% clinically significant improvement in patients treated. The cost comparison the program published is notable: drug costs of $1,700 per year for eight veterans, compared to an estimated $1.1–$3.7 million for 100 patients on esketamine (Spravato). The San Francisco VA and Ann Arbor VA also have active ketamine programs.

Community Care Network access:

Veterans who cannot access ketamine at a VA facility may be authorized to receive it through the Veterans Community Care Program, which contracts with private ketamine clinics. Ketamine Wellness Centers (operating across seven states) and Avesta Ketamine (DC, MD, VA) are among the providers serving veterans through this channel — at no out-of-pocket cost to eligible veterans with an authorized referral.

Research investment:

The VA funded its first psychedelic study in December 2024 — $1.5 million for MDMA-assisted therapy for PTSD through a joint Brown/Yale program. Nine VA facilities are now conducting psychedelic trials.

At the federal legislative level, the Innovative Therapies Centers of Excellence Act (introduced March 2026 by Sen. Gallego) would designate five or more VA facilities as psychedelic research centers with $30 million per year in funding.

Texas IMPACT Program

In June 2025, Governor Abbott signed SB 2308/HB 3717 establishing the largest publicly funded psychedelic research initiative in US history: $50 million in state funding matched by $50 million in private funding, totaling $100 million.

The IMPACT program focuses on ibogaine clinical trials for veterans with TBI, PTSD, and opioid dependency. It is led by UTHealth Houston and UTMB Galveston, with participation from Baylor, Texas Tech, Texas A&M, and Dell Medical School.

The program was inspired in part by a Stanford Nature Medicine study (n=30 male Special Operations veterans with TBI) showing that a single ibogaine dose produced 88% reduction in PTSD symptoms at one month, with 71% no longer meeting PTSD diagnostic criteria at one year.

IMPACT is currently in setup and planning. Full FDA-pathway clinical trial progress is estimated at six or more years — this is a long-horizon investment, not an immediately available treatment path.

Missouri Psilocybin Legislation for Veterans

Missouri has seen significant legislative activity around psychedelic therapy for veterans, though no bill has been signed into law as of March 2026.

The relevant active legislation is HB 1717 (2026 session, Rep. Richard West), with predecessors HB 829/SB 786 (2025) and HB 1830/SB 768 (2024). These bills would allow veterans 21 and older with PTSD, depression, or substance use disorders to access psilocybin while enrolled in clinical trials. HB 1717 passed its Veterans and Armed Forces Committee 20-0 but has stalled before reaching the governor.

For a full update on psilocybin legislation across all states, including Colorado's and Oregon's operational programs where veterans can legally access psilocybin therapy now, see our guide to psilocybin therapy legal states in 2026.

MDMA Therapy Context

MDMA-assisted therapy was widely considered the most promising PTSD treatment in development until August 2024, when the FDA rejected Lykos Therapeutics' application. An FDA advisory committee had voted 9-2 against effectiveness, citing concerns about trial methodology and functional unblinding. The company subsequently collapsed, cutting 75% of its workforce, and renamed itself Resilient Pharmaceuticals in August 2025.

The FDA recommended a new Phase 3 trial with an active comparator. Earliest potential reapproval under that path: 2027.

Meanwhile, COMPASS Pathways pivoted into PTSD in January 2026, when the FDA accepted an IND application for COMP202 psilocybin for PTSD. COMPASS's preliminary Phase 2 results (Journal of Psychopharmacology, September 2025, n=22) showed a 29.5-point CAPS-5 reduction at 12 weeks. See our psilocybin FDA approval tracker for ongoing updates.

Cost and Access

Ketamine pricing for PTSD is the same as for depression — there is no PTSD-specific pricing.

Per session: $400–$800
Standard 6–8 infusion course: $3,000–$6,000
Spravato: Covered by insurers for depression indications only, not PTSD. However, many PTSD patients have comorbid treatment-resistant depression, and Spravato coverage may be obtainable for the depression component.

For a full breakdown by state and treatment type, see our ketamine therapy cost guide.

Veteran-Specific Access Options

VA Community Care Network: Veterans may receive ketamine at private clinics at no out-of-pocket cost with an authorized referral. Contact your VA primary care team or mental health coordinator to request a Community Care referral.

Nonprofits providing financial assistance:

VETS (Veterans Exploring Treatment Solutions): Has served 1,200+ veterans
Heroic Hearts Project: Connects veterans to psychedelic therapy, including ketamine
The Ketamine Fund: 25+ physicians providing free infusions
Once A Soldier: Grants for IV therapy

Search our directory to find a ketamine clinic near you →

The Bottom Line

The honest summary of ketamine for PTSD is that the evidence is mixed. Small trials — particularly the Mount Sinai studies — produced large effect sizes. The largest controlled trial in veterans found no benefit over placebo. Meta-analysis after publication-bias correction lands at non-significant.

What makes the field interesting right now is the combination therapy hypothesis: that ketamine's neuroplasticity window may make it a powerful adjunct to trauma-focused psychotherapy, rather than a standalone treatment. The 2025 results from studies combining ketamine with Written Exposure Therapy and psychedelic-assisted protocols suggest this is a productive direction.

For veterans specifically, the landscape is more accessible than the official VA guideline suggests — through VA programs that operate despite the guideline, Community Care Network referrals, and nonprofit funding programs.

If you're evaluating ketamine for PTSD, go in with realistic expectations: this is not an approved treatment with an established protocol. Choose a clinic with specific PTSD experience, ask about whether they pair infusions with trauma-focused therapy, and understand that the evidence base for ketamine-plus-psychotherapy is promising but still maturing.

For the sister article on ketamine for depression — a condition with a stronger and more consistent evidence base — see Ketamine Therapy for Depression.

Sources

Feder A et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry, 2014
Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. AJP, 2021
Abdallah CG, Krystal JH et al. Ketamine treatment for PTSD in veterans — the CAP trial. Neuropsychopharmacology, 2022
Borgogna NC et al. Ketamine for PTSD meta-analysis (6 RCTs, n=221). European Journal of Psychotraumatology, 2024
Feder A et al. Ketamine plus Written Exposure Therapy for PTSD (n=13). Journal of Clinical Psychiatry, 2025
Beaglehole B et al. IM ketamine for treatment-refractory PTSD RCT (n=33). BJPsych Open, 2025
MacConnel P et al. IV ketamine with psychedelic-therapy elements (n=117). Journal of Psychopharmacology, 2025
Central Arkansas VA Mental Health Ketamine program outcomes. VA Marketplace
Nayak SM et al. Ibogaine for TBI veterans (Stanford, n=30). Nature Medicine, 2024
Pfeiffer PN et al. Clinical outcomes of IV ketamine for depression in the VA. Journal of Clinical Psychiatry, 2024
S.4031 — Innovative Therapies Centers of Excellence Act. Congress.gov

This article is for informational purposes only and does not constitute medical advice. Ketamine is not FDA-approved for PTSD. Always consult a qualified healthcare provider before beginning any treatment program. Clinical data cited reflects published peer-reviewed research as referenced.